https://www.selleckchem.com/pr....oducts/fti-277-hcl.h
BC2001 demonstrated improved local control with the addition of chemotherapy to radiotherapy in 360 patients with muscle-invasive bladder cancer. To establish whether such benefit remained in BC2001 patients who received prior neoadjuvant chemotherapy. A total of 117 patients (33%) received neoadjuvant chemotherapy and were randomised to radiotherapy with (48%) or without (52%) concomitant chemotherapy. Patients were recruited between August 2001 and April 2008 from 28 UK centres. Platinum-based neoadjuvant chemotherapy, followed by
Like
Comment
Share
